Success Story: NIW Approved and EB-1 Approval Secured Under Premium Processing for a Bioinformatics Specialist Advancing Cancer Immunotherapy
Client’s Testimonial:
"I had an excellent experience working with Wegreened on my EB1B and EB2-NIW cases, both approved. The process was smooth, efficient, and handled with a high level of professionalism. Their team was always responsive and addressed my questions promptly. I highly recommend their services.”
On March 6th, 2025, and February 19th, 2026, we received another I-140 NIW (National Interest Waiver) and EB-1B (Outstanding Professors and Researchers) Approvals for a Computational Biologist in the Field of Cancer Research (Approval Notice).
General Field: Cancer Research
Position at the Time of Case Filing: Computational Biologist
Country of Origin: France
State of Residence at the Time of Filing: New York
Approval Notice Date: March 6th, 2025 & February 19th, 2026 (NIW&EB1B)
Processing Time: 2 months, 3 days (NIW), and 17 days (EB1B) (Premium Processing Requested)
Case Summary:
Client Background and Proposed Endeavor
The client holds an M.S. in bioinformatics and is currently employed as a computational biologist at a U.S.-based cancer research institution. The client’s work centers on uncovering immune regulatory mechanisms that drive tumor progression, metastasis, and therapeutic resistance, with the goal of advancing immunotherapies for challenging cancers, including leukemia, melanoma, and colorectal cancer.
A key theme in the petition narrative was consistency: the client’s research combined translational oncology and tumor immunology to move beyond theory and toward strategies that can improve how patients are matched to therapies and how next-generation treatments are engineered. The client is particularly recognized for contributing to a CAR T-cell therapy approach, a line of work that reflects both technical originality and clear clinical relevance.
National Significance of the Research
In the NIW filing, we framed the client’s endeavor as work of substantial merit and national importance because it targets a persistent U.S. healthcare priority: improving cancer outcomes by strengthening the effectiveness and durability of immunotherapy. We emphasized how the client’s research helps clarify why tumors evade immune attack, why some treatments fail, and how immune-based therapies can be designed and optimized to deliver more targeted and lasting responses.
This positioning was not presented as a generalized public-health claim. Instead, the petition tied the client’s research to concrete translational pathways, including CAR T-cell therapy development, the identification of predictive immune biomarkers, and the characterization of signaling mechanisms that influence therapy resistance. These are the types of advances that can improve treatment decision-making and expand the reach of immunotherapy to more patients.
Impressive Credentials and Achievements
To establish a clear record of professional standing, our legal team documented a strong record of peer-validated output and research uptake:
- Publications: 11 peer-reviewed journal articles, 3 conference abstracts, and 2 preprints
- Citations: 162 citations to the published body of work
- Peer review: recognition by journals seeking the client’s service to review manuscripts, reflecting field trust in the client’s scientific judgment
Importantly, the case presentation treated these metrics as evidence, not as conclusions. Publication volume alone is common in research careers, so we emphasized what the record suggested to an adjudicator: sustained productivity in a specialized area, paired with measurable uptake that indicates independent researchers are relying on the client’s findings. Likewise, the manuscript review service was framed as a credibility signal that the community views the client as qualified to help uphold publication standards.
Expert Endorsements
We also included 6 expert recommendation letters to corroborate the client’s standing and the significance of the work. These letters reinforced how the client’s contributions are used and valued by other professionals in aligned areas of cancer research and immunotherapy development.
“[Client’s] employment at this center, his revolutionary work with cancer biomarkers, and his dedication to cancer research confirm his position at the forefront of his field.”
The Result
Utilizing premium processing, the client achieved NIW approval on March 6, 2025, and later secured EB-1 approval on February 19, 2026. Together, these outcomes reflect USCIS’s recognition of a record built on original contributions, independent research reliance, and credible expert support, all aligned with a forward-looking endeavor expected to advance cancer immunotherapy and improve patient outcomes in the United States.